Lymphoma

Relapsed or Refractory Lymphoid Malignancies

  • PSOC 2502: ​A Phase I Study of Bendamustine/Treanda, Rituximab, Etoposide and Carboplatin for Patients with Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas
  • MAGNIFY:  Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

For more information, contact Cheryl Patz, RN, OCN, CCRC, at 360-788-8238.